HealthAI imageRactigen Presents First Human RNA Activation Data in Duchenne Muscular Dystrophy
Ractigen Therapeutics will present first-in-human clinical data showing RNA activation-mediated utrophin upregulation in Duchenne muscular dystrophy (DMD) at the 31st World Muscle Society Congress in Hiroshima, Japan. The data from an ongoing trial demonstrate safety, tolerability, and molecular evidence of utrophin increase, a mutation-independent therapeutic approach for DMD. Principal Investigator Professor Yi Dai will deliver the presentation on October 3, 2026.
Pr Newswire Apac··Hiroshima


